Floatz logo

Pembrolizumab

Gastroesophageal Junction Adenocarcinoma

Eikon Therapeuticsmonoclonal_antibodyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
73/ 100

Competitive context

109 Active assets in the Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →